Anti-inflammatory use during surgery could improve cancer outcomes

surgery
Credit: CC0 Public Domain

The world's first clinical trial (SURGUVANT) evaluating anti-inflammatory use at the time of surgery in colon cancer patients to improve their cancer outcome has been published in scientific journal, BMC Cancer.

The research successfully tested an anti-inflammatory agent with anti-cancer properties known as Taurolidine in the SURGUVANT trial which was funded by a grant from Geistlich Pharma AG, Wolhusen, Switzerland. The research was undertaken by researchers at RCSI in Dublin in collaboration with the Cork University Hospital group, University College Cork, Mercy University Hospital and the Bon Secours Hospital, Cork led by Professor Paul Redmond, RCSI Council member and Chair of Surgery at Cork University Hospital and Mr Peter O'Leary, CUH Department of Surgery.

The Surguvant trial examined a link between surgical inflammation and the recurrence of cancer. The trial randomised patients undergoing for colon cancer to either a placebo or 2 percent Taurolidine solution. The trial reported that important components of the to surgery that have been shown to propagate tumour cell growth, can be attenuated successfully without compromising patient safety.

"We are delighted that this important clinical trial could be performed in Ireland. The Surguvant trial is the first of its kind to be performed worldwide showing that it is safe to use Taurolidine in this critical period of time for cancer patients where they are exposed to an inflammatory response necessary for wound healing but which can be potentially detrimental to their outcome," said Professor Redmond. "Now that we have proven the safety of this treatment strategy, it remains to be demonstrated if targeting the inflammatory response to surgery will lead to improved outcomes for . We hope to do this in much larger future trials."


Explore further

New Omega-3 trial for secondary liver cancer surgery

More information: H. Paul Redmond et al. RandomiSed clinical trial assessing Use of an anti-inflammatoRy aGent in attenUating peri-operatiVe inflAmmatioN in non-meTastatic colon cancer – the S.U.R.G.U.V.A.N.T. trial, BMC Cancer (2018). DOI: 10.1186/s12885-018-4641-x
Journal information: BMC Cancer

Citation: Anti-inflammatory use during surgery could improve cancer outcomes (2018, September 4) retrieved 13 June 2021 from https://medicalxpress.com/news/2018-09-anti-inflammatory-surgery-cancer-outcomes.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments